Progress in Locoregional Interventional Therapy of Primary Hepatocellular Carcinoma

Primary hepatocellular carcinoma (HCC) is the sixth most common malignant tumor in the world, and ranks third in tumor-related deaths. The incidence and mortality of HCC in China are among the top five in both men and women, and are increasing year by year, while less than 30% of patients can be surgically resected. With the continuous development of medical technology, interventional therapy has played a key role in the treatment of HCC. This article reviews the latest progress of interventional therapy such as transarterial chemoembolization, transarterial radioembolization, radiofrequency ablation and microwave ablation, as well as interventional therapy combined with molecular targeted therapy and immunotherapy.